MX2019014409A - Métodos y composiciones para tratar somnolencia excesiva. - Google Patents

Métodos y composiciones para tratar somnolencia excesiva.

Info

Publication number
MX2019014409A
MX2019014409A MX2019014409A MX2019014409A MX2019014409A MX 2019014409 A MX2019014409 A MX 2019014409A MX 2019014409 A MX2019014409 A MX 2019014409A MX 2019014409 A MX2019014409 A MX 2019014409A MX 2019014409 A MX2019014409 A MX 2019014409A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating excessive
excessive sleepiness
sleepiness
Prior art date
Application number
MX2019014409A
Other languages
English (en)
Inventor
Lawrence Patrick Carter
Yuan Lu
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64455104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019014409(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2019014409A publication Critical patent/MX2019014409A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

La presente invencion esta relacionada con compuestos de carbamoil fenilalaninol y metodos para usar los mismos para tratar trastornos; la invencion esta ademas relacionada con el desarrollo de metodos para tratar somnolencia excesiva en un sujeto, por ejemplo, debido a narcolepsia o apnea obstructiva del sueno, con el resultado sorprendente de que niveles "normales de desvelo se logran con base en pruebas de somnolencia objetivas y subjetivas estandar.
MX2019014409A 2017-06-02 2018-06-01 Métodos y composiciones para tratar somnolencia excesiva. MX2019014409A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514176P 2017-06-02 2017-06-02
PCT/US2018/035532 WO2018222954A1 (en) 2017-06-02 2018-06-01 Methods and compositions for treating excessive sleepiness

Publications (1)

Publication Number Publication Date
MX2019014409A true MX2019014409A (es) 2022-03-17

Family

ID=64455104

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014409A MX2019014409A (es) 2017-06-02 2018-06-01 Métodos y composiciones para tratar somnolencia excesiva.

Country Status (11)

Country Link
US (4) US10959976B2 (es)
EP (1) EP3630072A4 (es)
JP (1) JP2020528075A (es)
KR (2) KR20200016889A (es)
CN (1) CN111201014A (es)
AU (1) AU2018278332B2 (es)
BR (1) BR112019025286A2 (es)
CA (1) CA3065522A1 (es)
MX (1) MX2019014409A (es)
PH (1) PH12019502723A1 (es)
WO (1) WO2018222954A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
MX2019014409A (es) 2017-06-02 2022-03-17 Jazz Pharmaceuticals Ireland Ltd Métodos y composiciones para tratar somnolencia excesiva.
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
WO2021001457A1 (en) * 2019-07-04 2021-01-07 Sandoz Ag Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
US10940133B1 (en) * 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
AU2022340824A1 (en) * 2021-09-03 2024-02-29 Axsome Therapeutics Methods and compositions for ameliorating biomarkers associated with cardiovascular risk using (r)-2-amino-3-phenylpropyl carbamate
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11771666B1 (en) 2022-12-30 2023-10-03 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
CZ285762B6 (cs) 1993-06-10 1999-11-17 Eli Lilly And Company Farmaceutický prostředek vhodný pro prevenci dávení a zvracení a pro ošetřování sexuální dysfunkce savců a jeho použití
DE9311004U1 (de) 1993-07-23 1993-10-14 Mauser Werke Gmbh Palettencontainer
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
ES2170878T3 (es) 1996-10-10 2002-08-16 Sk Corp Compuestos de o-carbamoil-fenilalaninol y sus sales farmaceuticamente utiles.
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
AU779354B2 (en) 1998-12-23 2005-01-20 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
PL364639A1 (en) 2001-02-27 2004-12-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating anxiety disorders
PT1408953E (pt) 2001-02-27 2006-07-31 Ortho Mcneil Pharm Inc Compostos carbamato para utilizacao na prevencao ou tratamento do disturbio bipolar
MXPA03007719A (es) 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o el tratamiento de transtornos neurodegenerativos.
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
WO2004010970A1 (en) 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP2008518921A (ja) 2004-10-28 2008-06-05 エスケー ホルディングス カンパニー リミテッド うつ病のための補助療法
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
JP5298334B2 (ja) 2005-06-22 2013-09-25 エスケー ホルディングス カンパニー リミテッド 性機能障害を治療する方法
EA019935B1 (ru) 2005-07-26 2014-07-30 Янссен Фармацевтика Н.В. Способы лечения алкогольной абстиненции
JP2010506845A (ja) 2006-10-13 2010-03-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フェニルアルキルアミノカルバメート組成物
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
EP2445490B1 (en) 2009-06-22 2023-02-08 SK Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
BR112012028035B1 (pt) 2010-05-04 2021-05-25 Jazz Pharmaceuticals, Inc. formulação de liberação imediata
EP2392325A1 (en) 2010-06-04 2011-12-07 Universitätsklinikum Münster Compounds for the prevention and/or treatment of osteoarthrosis
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
PT2968208T (pt) 2013-03-13 2022-10-28 Aerial Biopharma Llc Tratamento da cataplexia
CN110638805A (zh) 2013-07-12 2020-01-03 爵士制药国际Iii有限公司 促进吸烟停止
PL3021838T3 (pl) 2013-07-18 2021-03-08 Jazz Pharmaceuticals Ireland Limited Leczenie otyłości
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
MX2019014409A (es) 2017-06-02 2022-03-17 Jazz Pharmaceuticals Ireland Ltd Métodos y composiciones para tratar somnolencia excesiva.
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Also Published As

Publication number Publication date
US20200163927A1 (en) 2020-05-28
CA3065522A1 (en) 2018-12-06
KR20230145525A (ko) 2023-10-17
KR20200016889A (ko) 2020-02-17
US11648232B2 (en) 2023-05-16
AU2018278332A1 (en) 2020-01-30
EP3630072A1 (en) 2020-04-08
AU2018278332B2 (en) 2022-05-19
US10959976B2 (en) 2021-03-30
US11865098B1 (en) 2024-01-09
WO2018222954A1 (en) 2018-12-06
US10912754B2 (en) 2021-02-09
US20210205257A1 (en) 2021-07-08
JP2020528075A (ja) 2020-09-17
EP3630072A4 (en) 2021-03-10
BR112019025286A2 (pt) 2020-06-23
CN111201014A (zh) 2020-05-26
US20200281886A1 (en) 2020-09-10
PH12019502723A1 (en) 2020-07-13
US20240033243A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
PH12019502723A1 (en) Methods and compositions for treating excessive sleepiness
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
GEP20227387B (en) Methods and compositions for treating sleep apnea
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
MX2015007531A (es) Composiciones de gamma-hidroxibutirato y sus usos para el tratamiento de trastornos.
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
UY30097A1 (es) Usos terapeuticos de inhibidores de rtp801
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CO2021015264A2 (es) Inhibidores de dihidroorotato deshidrogenasa
PH12019501408A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
MX2021008400A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2010010303A (es) Nuevos compuestos de acido ribonucleico de pequeña interferencia para inhibir rtp801.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
PH12019502886A1 (en) Methods for increasing growth of beneficial bacteria in the gastrointestinal tract
MX2020001146A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
TN2011000319A1 (en) Substituted quinazoline compounds
MX2019012086A (es) Composiciones y métodos para tratar o prevenir trastornos relacionados con la permeabilidad intestinal.
CY1118297T1 (el) Θεραπευτικες χρησεις της εσλικαρβαζεπινης
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.